Clinical trials are an excellent way to collect data for AML treatments and to get new therapies approved by the FDA. However, they are also long and costly.
Thankfully, patients are doing so well on therapies that progression-free survival and other primary endpoint data often take several years, even a decade or more, to collect.
Additionally, the clinical trial process understandably requires time to fund, set up, be approved, enroll a sufficient number of patients, conduct the trial, and manage the complications, delays, and potential red tape that can come along the way. This can mean that from the time an investigator has a research idea to the time the clinical trial actually starts, it could be a matter of years.
All of this time means millions of dollars are required to fund and support these trials. This often makes it unrealistic for a researcher to conduct an independent clinical trial rather than one that pharmaceutical companies fund.
Real-world studies allow data to be collected quickly and efficiently. What is taking years to collect in the clinical setting can take a mere matter of months.
HealthTree Research Hub will allow rapid real-world data requests to be granted to blood cancer researchers to support meaningful and quicker studies.
How?
Blood cancer patients can't afford to wait years or decades to get better and personalized treatments that can improve their quality of life. Real-world data studies through HealthTree Research Hub can accelerate necessary investigations and surveys to significantly improve patient care and lead to better treatments and cures for each and every patient.
Hear how blood cancer specialist, Dr. Irene Ghobrial, feels about HealthTree's research initiatives here:
Participate in AML research as or on behalf of an AML patient by completing one of the following:
Clinical trials are an excellent way to collect data for AML treatments and to get new therapies approved by the FDA. However, they are also long and costly.
Thankfully, patients are doing so well on therapies that progression-free survival and other primary endpoint data often take several years, even a decade or more, to collect.
Additionally, the clinical trial process understandably requires time to fund, set up, be approved, enroll a sufficient number of patients, conduct the trial, and manage the complications, delays, and potential red tape that can come along the way. This can mean that from the time an investigator has a research idea to the time the clinical trial actually starts, it could be a matter of years.
All of this time means millions of dollars are required to fund and support these trials. This often makes it unrealistic for a researcher to conduct an independent clinical trial rather than one that pharmaceutical companies fund.
Real-world studies allow data to be collected quickly and efficiently. What is taking years to collect in the clinical setting can take a mere matter of months.
HealthTree Research Hub will allow rapid real-world data requests to be granted to blood cancer researchers to support meaningful and quicker studies.
How?
Blood cancer patients can't afford to wait years or decades to get better and personalized treatments that can improve their quality of life. Real-world data studies through HealthTree Research Hub can accelerate necessary investigations and surveys to significantly improve patient care and lead to better treatments and cures for each and every patient.
Hear how blood cancer specialist, Dr. Irene Ghobrial, feels about HealthTree's research initiatives here:
Participate in AML research as or on behalf of an AML patient by completing one of the following:
about the author
Audrey Burton-Bethke
Audrey is a content writer and editor for the HealthTree Foundation. She originally joined the HealthTree Foundation in 2020. Audrey loves spending time with her supportive husband, energetic four-year-old, and new baby.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.